Suppliers and packagers for narcan

narcan

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Emergent	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411	NDA	A-S Medication Solutions	50090-2422-0	2 VIAL, SINGLE-DOSE in 1 PACKAGE (50090-2422-0) / .1 mL in 1 VIAL, SINGLE-DOSE	2017-01-24
Emergent	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411	NDA AUTHORIZED GENERIC	A-S Medication Solutions	50090-5908-0	2 VIAL, SINGLE-DOSE in 1 CARTON (50090-5908-0) / .1 mL in 1 VIAL, SINGLE-DOSE	2021-12-20
Emergent	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1240-1	.1 mL in 1 VIAL, SINGLE-DOSE (51662-1240-1)	2018-10-15
Emergent	NARCAN	naloxone hydrochloride	SPRAY, METERED;NASAL	208411	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1240-2	2 VIAL, SINGLE-DOSE in 1 PACKAGE (51662-1240-2) / .1 mL in 1 VIAL, SINGLE-DOSE	2018-10-15

Suppliers for the Pharmaceutical Drug: Narcan

Last updated: July 29, 2025

Introduction

Narcan, known generically as naloxone, has become a critical tool in combating opioid overdoses worldwide. As an opioid antagonist, Narcan rapidly reverses the effects of opioid poisoning, saving countless lives. The demand for naloxone has surged amid the opioid crisis, prompting stakeholders—governments, healthcare providers, and pharmacies—to seek reliable suppliers. This article provides a comprehensive analysis of the key suppliers for Narcan, examining their production capabilities, market share, regulatory landscape, and strategic positioning.

Overview of Narcan (Naloxone) Market

The global naloxone market has experienced exponential growth over the past decade. This expansion aligns with increased awareness of opioid-related fatalities, federal funding initiatives, and policy mandates for widespread naloxone distribution. The pharmaceutical landscape for naloxone includes several major players, ranging from large multinational corporations to specialized generic manufacturers.

Major Suppliers of Narcan

1. Adapt Pharma (A subsidiary of Boehringer Ingelheim)

Overview: Adapt Pharma pioneered the development and commercialization of Narcan nasal spray in the United States. Boehringer Ingelheim acquired Adapt Pharma in 2019, further expanding distribution reach and manufacturing capacity.

Manufacturing and Supply Capabilities:
Adapt Pharma was the first to secure FDA approval for Narcan nasal spray in 2015 and developed a user-friendly intranasal formulation that became top-selling. Post-acquisition, Boehringer Ingelheim amplified production, leveraging its global manufacturing infrastructure.

Market Position:
As the flagship provider of OTC Narcan nasal spray in the U.S., Adapt Pharma’s influence remains significant, especially within emergency medical services and community distribution programs.

2. Pfizer

Overview:
Pfizer is a key global pharmaceutical giant producing Naloxone hydrochloride injections and auto-injectors like Evzio, an autoinjector for opioid overdose reversal.

Product Portfolio and Supply:
Pfizer’s Evzio has served as an injectable alternative to nasal sprays, often utilized in clinical settings and by emergency responders. Although Pfizer announced in 2019 that it would cease manufacturing Evzio due to declining sales, its legacy products continue to influence market supply and alternative formulations.

Regulatory & Supply Dynamics:
Pfizer’s extensive manufacturing capacity and research expertise make it a notable supplier, though supply constraints may occur as production shifts or discontinuations ensue.

3. Neon Pharma / Teva Pharmaceutical Industries

Overview:
Teva Pharmaceuticals, a leading generic drug manufacturer, acquired Neon Pharma in 2018, expanding its portfolio to include naloxone products.

Product Offerings and Supply:
Teva produces generic naloxone injectables and nasal formulations, with a focus on affordability and accessibility worldwide. Their global manufacturing footprint and established generic operations enable large-scale supply.

Market Impact:
Teva's participation diversifies supply sources, contributing to market stability, especially in regions relying heavily on generic medications.

4. Hikma Pharmaceuticals

Overview:
Hikma, a Jordan-based pharmaceutical company, produces generic naloxone formulations supplied primarily in Europe, the Middle East, and Africa.

Capabilities:
Hikma offers injectable naloxone and has obtained regulatory approvals to distribute in multiple jurisdictions. Its focus on affordable generics and partnerships with distributors makes it a vital regional supplier.

Strategic Positioning:
Hikma complements larger global players by serving markets with limited access to branded formulations.

5. Generic Manufacturers and Regional Suppliers

Numerous regional and local pharmaceutical companies supply generic naloxone formulations, especially in emerging markets. These include firms like Amphastar Pharmaceuticals (USA), and others operating under regulatory compliance to meet local demand.

Manufacturing and Supply Chain Considerations

• Regulatory Approvals:
  Suppliers must secure approvals from agencies like the FDA for products intended for public health use. FDA issued Emergency Use Authorizations (EUAs) during the COVID-19 pandemic, facilitating wider distribution of Naloxone products.

• Manufacturing Capacity:
  Capacity expansion remains critical, especially considering the heightened demand following the opioid crisis. Companies like Boehringer Ingelheim have invested in scalable manufacturing, including nasal spray and injectable forms.

• Supply Chain Challenges:
  The global pharmaceutical supply chain faced disruptions amid the pandemic, influencing availability. Suppliers investing in diversified manufacturing and regional manufacturing hubs mitigate this risk.

Regulatory Landscape and Market Access

Narcan’s regulatory status varies across regions:

• In the U.S., the FDA approved multiple formulations, including nasal spray (Adapt Pharma/Boehringer Ingelheim), auto-injectors (Evzio by Pfizer), and generic injectables.
• European regulators approve nasal and injectable naloxone, with regional suppliers such as Hikma supplying markets outside North America.
• The US government’s initiatives, including the SAMHSA (Substance Abuse and Mental Health Services Administration), procure large quantities for distribution, influencing supplier strategies.

Competitive Strategies Among Suppliers

• Partnerships with Governments and NGOs:
  Suppliers often collaborate with public health agencies to ensure broad access, including bulk purchasing agreements.

• Formulation Innovations:
  Focus on developing user-friendly, stable, and cost-effective formulations helps suppliers differentiate in the market.

• Pricing and Accessibility:
  Generics manufacturers leverage economies of scale to provide affordable naloxone, vital for public health programs.

• Supply Security and Capacity Expansion:
  Companies investing in capacity expansion mitigate shortages and meet surging demand driven by policy initiatives.

Future Outlook

The demand for Narcan is projected to rise, given increasing opioid overdose deaths globally. Suppliers are expected to:

• Expand manufacturing capacity.
• Develop alternative formulations (e.g., auto-injectable, needle-free devices).
• Strengthen partnerships with health authorities and community organizations.
• Address logistical issues to enhance global distribution, especially in underserved regions.

Emerging market entries and generic manufacturers will continue to diversify the landscape, promoting affordability and access.

Key Takeaways

• Leading suppliers of Narcan include Adapt Pharma/Boehringer Ingelheim, Pfizer, Teva, Hikma, and numerous regional manufacturers.
• The market is characterized by a mix of branded products, generics, and regional formulations tailored to specific markets.
• Production capacity and regulatory approval are critical factors influencing supply stability.
• Strategic partnerships, formulation innovation, and capacity expansion drive supplier competitiveness.
• Growing global demand underscores the importance of diversified, resilient supply chains.

FAQs

1. Who are the primary suppliers of Narcan in the U.S.?
The primary suppliers include Adapt Pharma (a subsidiary of Boehringer Ingelheim), Pfizer (through its Evzio auto-injector), and various generic manufacturers like Amphastar Pharmaceuticals.

2. Are there generic alternatives to branded Narcan?
Yes. Multiple generic manufacturers produce naloxone formulations, including injectables and nasal sprays, offering more affordable options for public health programs.

3. How has the COVID-19 pandemic affected Narcan supply chains?
The pandemic caused disruptions in manufacturing and logistics, potentially leading to temporary shortages. Manufacturers responded by increasing capacity and diversifying supply sources.

4. What regulatory approvals are necessary for Narcan products?
Approval from agencies like the FDA is required for U.S. products, including indications, formulations, and manufacturing standards. Similar approvals are necessary in other markets.

5. What is the outlook for Narcan suppliers in the future?
Demand is expected to grow, prompting firms to expand manufacturing, innovate with new formulations, and deepen collaborations to ensure broader access worldwide.

---

Sources

1. [1] U.S. Food and Drug Administration. FDA Approves First Nasal Spray for Overdose Reversal. 2015.
2. [2] Boehringer Ingelheim. Adapt Pharma’s Narcan nasal spray: Product portfolio.
3. [3] Pfizer. Evzio auto-injector product details and market outlook.
4. [4] Teva Pharmaceuticals. Naloxone Product Portfolio.
5. [5] Hikma Pharmaceuticals. Regional drug distribution and formulations.